2014

Twenty-Year Veteran of Biotechnology Industry Joins Sofinnova Ventures Harold E. Selick, PhD, an Alumnus of Affymax, Protein Design Labs and Camitro,

Will Increase Sofinnova Venture's Investment Activity in Biotech

Platform Companies.



    SAN FRANCISCO, May 22 /PRNewswire/ -- Sofinnova Ventures, a venture firm
 investing in early stage information technology and life sciences companies,
 today announced that Harold E. "Barry" Selick, PhD has joined the firm as a
 Venture Partner.  Selick has held scientist and senior executive positions
 with several successful biotechnology companies, including Affymax, Protein
 Design Labs, Anergen and Camitro.
     With the addition of Selick, Sofinnova Ventures will increase its
 investment activity in biotech platform and drug discovery companies.  The
 firm's investments in biotechnology include AlgoRx, Actelion, David
 Pharmaceuticals, Exhale Therapeutics, KaloBios, InterMune Pharmaceuticals,
 Novocea and Seattle Genetics.
     "We are bringing Barry on board to give even more strength to our life
 science investing," commented Michael Powell, PhD, a Managing Director of
 Sofinnova Ventures.  "His scientific expertise will enable him to distinguish
 the most promising biotechnology companies for Sofinnova to invest in, and his
 strong operational background will make him perfectly suited to take on
 interim management roles for our young start-ups."
     "I am very excited to be joining such an accomplished team of investors
 and entrepreneurs and am looking forward to contributing my own experience in
 helping to strengthen and expand Sofinnova's portfolio of innovative and
 inspiring biotechnology ventures," said Selick.
     Selick co-founded Camitro in January 1999.  As President and CEO of the
 company, he recruited a world-class team of scientists and entrepreneurs,
 oversaw the creation and commercialization of Camitro's technology for
 pharmaceutical drug discovery, established two corporate sites in Menlo Park,
 California and Cambridge, the United Kingdom, and initiated and led the
 Camitro team in negotiations that resulted in its acquisition by the drug
 discovery company Arqule in 2001 for $95 million.
     Prior to Camitro, Selick was Vice President, Research for Affymax Research
 Institute, the wholly owned drug discovery technology development center for
 Glaxo Wellcome.  He directed activities in combinatorial chemistry-based drug
 discovery, with particular emphasis on the development of technologies for
 improving the process of lead optimization.  He was also Senior Scientist,
 Head of Molecular Biology at Anergen, Inc. (acquired by Corixa) and a Staff
 Scientist at Protein Design Labs, where he was co-inventor of the technology
 underlying the creation of fully humanized antibodies.  He applied this
 technology to the creation of the "Smart anti-TAC" antibody, which was
 successfully developed and commercialized by Roche as "Zenapax", for treating
 kidney transplant rejection.
     Selick was a Damon Runyon-Walter Winchell Cancer Fund Fellow with
 Professor Bruce Alberts (currently President of the National Academy of
 Sciences) and an American Cancer Society Fellow at the University of
 California, San Francisco, School of Medicine.  He earned a Ph.D. in Biology
 and a BA in Biophysics from the University of Pennsylvania.
 
     About Sofinnova Ventures
     Sofinnova Ventures is part of a global organization with offices in France
 and the United States.  With a U.S. base in San Francisco, Sofinnova was
 founded in 1972 and is one of the oldest venture capital firms.  The firm
 emphasizes a diversified investment strategy through financing seed and
 early-stage companies in the communications, information technology and life
 science sectors.  Sofinnova's mission is to create value by providing
 entrepreneurs with the collective resources, experience and network necessary
 to build early-stage companies into profitable businesses.  With strong ties
 to Europe's leading financial, technology and venture organizations, Sofinnova
 helps U.S. companies rapidly enter Europe's growing markets, and European
 companies to develop a strong presence in U.S. markets.  Historically,
 Sofinnova Ventures has been associated with leading companies such as Biogen,
 Collagen, Genentech, Printronix, Tandon and Tandem Computers.  More recently,
 Sofinnova has invested in Actelion, Aviron, InterMune Pharmaceuticals,
 Millennium Pharmaceuticals, Phone.com, Premisys, Nishan Systems and
 Tumbleweed. For more information, visit www.sofinnova.com.
 
                      Tell Us What You Think -- Click Here
                http://tbutton.prnewswire.com/prn/11690X38669832
 
 

SOURCE Sofinnova Ventures

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

 

PR Newswire Membership

Fill out a PR Newswire membership form or contact us at (888) 776-0942.

Learn about PR Newswire services

Request more information about PR Newswire products and services or call us at (888) 776-0942.